Clinical Trials in Phoenix

Showing 8301-8320 of 12,606 trials

Validation of Non-Invasive Intracranial Pressure (ICP) Monitoring Device

NCT03865576

For purposes of validation, this study compares intracranial pressure measurements obtained with a novel self-calibrating, non-invasive, intracranial pressure measuring (ICP) device, with the values obtained from (a) patients in an intensive care unit (ICU) whose meet standard clinical indications for ICP measurement and whose ICP is measured using gold-standard implanted intracranial instrumentation and in (b) ambulatory subjects who meet clinical indications for lumbar puncture.

Intracranial HypertensionAbnormality of Intracranial Pressure

Boston Neurosciences80 participantsStarted Mar 2019

Phoenix, Arizona, United States • Atlanta, Georgia, United States • Philadelphia, Pennsylvania, United States +1 more locations

TERMINATEDPhase 3< 1 mile

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

NCT01785771

An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day

Type 2 Diabetes

Intarcia Therapeutics100 participantsStarted May 2013

Birmingham, Alabama, United States • Gulf Shores, Alabama, United States • Chandler, Arizona, United States +48 more locations

Validation of Non-Invasive Intracranial Pressure (ICP) Monitoring Device

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Find Trials by Condition in Phoenix

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA

Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data

An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)

Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Study of Ixekizumab in Participants With Plaque Psoriasis

ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Inflammation and the Host Response to Injury (Trauma)

Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors